World Liver Day spotlight: Pioneering genetic solutions for liver disease

wold liver day social

Liver disease remains one of the leading causes of morbidity and mortality worldwide, presenting complex challenges in healthcare due to its multifaceted nature and often silent progression. Advancements in genetic research have begun to illuminate the pathways through which liver diseases develop, revealing that conditions like metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), are not only influenced by lifestyle but also by genetic predispositions.

Understanding these genetic factors is crucial to developing more precise diagnostic tools and targeted treatment strategies, marking a shift from a one-size-fits-all approach to more personalised medicine. This tailored approach promises greater efficacy in treatment outcomes and, importantly, the potential to halt the disease before symptoms worsen.

In honour of World Liver Day today, Sano has curated a list of our liver disease content to raise awareness and enhance understanding of liver health and the importance of research in this area. This collection offers insights into the latest genetic findings, showcases advancements in patient management, and highlights ongoing research initiatives. By providing these resources, we aim to support significant advancements in the treatment and prevention of liver diseases influenced by genetic factors, contributing to a broader dialogue on liver health.


Liver disease content

Recruitment case study_-3Case study: MASH

This case study discusses Sano’s ongoing collaboration with an integrated research organisation to identify and engage individuals with MASH genetic variants through a programme that includes a user-friendly online platform, site training, eligibility verification, genetic testing with counselling (both at no cost to participants), and personalised content distribution.

NASH insights report-1Report: The genetics of MASH

This report examines the complex realm of MASH genetics and its implications for innovative pharmaceutical and biotechnological solutions. It outlines the genetic factors driving MASH and offers insights that can shape the future of MASH research and drug development.

Frame 48095782-1Whitepaper: Precision in practice: Harnessing polygenic risk scores for targeted MASH therapies

This whitepaper explores how polygenic risk scores can be harnessed to drive decision-making in MASH management, offering new avenues for early prediction, precise diagnosis, and tailored treatment strategies. 

20Webinar: The genetics of metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH

In this webinar, Sano Partnerships Lead Lindsey Wahlstrom-Edwards hosts Wayne Eskridge and Neeraj Mistry in a discussion about the genetics of liver disease and how Sano and the Fatty Liver Foundation are working to drive progress in this area. 

10Webinar: An insider’s view on drug development in MASH with Dimitar Tonev

This webinar features Sano CEO Patrick Short in conversation with Dr. Dimitar Tonev about the MASH therapy landscape, the importance of genetics in trial recruitment, and the controversial topics that should be addressed to bring real improvements to MASH patients.

26Webinar: Non-invasive screening and genomics in MASLD with the Fatty Liver Foundation

Host Patrick Short chats with guests Wayne Eskridge and Dr. Neeraj Mistry in a webinar about early detection of MASLD and MASH using genetics, non-invasive liver testing, and other new technologies.

22-1Webinar: Inside MASH: Exploring detection, treatment, and future directions

In this webinar, Patrick is once again joined by Dr. Dimitar Tonev to discuss the evolving landscape of MASH, including diagnosis, treatment breakthroughs, and future directions.

Frame 4Podcast: Insights into precision medicine, fatty liver disease, and minimally invasive diagnostic tools with Dr. Mazen Noureddin 

In this episode of the Genetics Podcast, Patrick has a conversation with Dr. Mazen Noureddin, Professor of Medicine and Transplant Hepatologist at Houston Methodist Hospital, who has been involved in over 40 MASH clinical studies.

Group 2697Podcast: Alnylam's Josh Friedman on developing precision medicines for the “silent killer” MASH/MASLD 

On this episode of the podcast, Patrick is joined by Josh Friedman, former Senior Director of Research at Alnylam Pharmaceuticals and current SVP at Spyre Therapeutics. The discussion explores how RNA interference can be applied to treat common and rare genetic diseases, and dives deep into the genetics of MASLD and MASH.

Frame 4Podcast: Ochre Bio: Building an in-silico liver model and addressing the impact and challenges of developing new treatments

Patrick speaks to Quin Wills and Jack O’ Meara, Co-Founders of Ochre Bio, about why in-silico discoveries could be the road to faster and lower cost liver therapeutics, and the need for prioritising preventative measures against disease as humans live longer.


As we observe World Liver Day, Sano is proud to contribute to the discourse on liver health with these resources. By harnessing the power of genetic insights and advanced diagnostics, we can move beyond conventional approaches and towards more tailored, proactive strategies that effectively address the unique complexities of each patient’s condition. We encourage researchers, clinicians, and stakeholders in liver health to explore these resources and join us in pioneering a future where precision medicine transforms the landscape of liver disease management and patient care.

Get in touch